MediView XRa medical technology company using augmented reality, announced it received FDA 510(k) approval for its AR surgical navigation system called the XR90.
XR90 is an augmented reality visualization and surgical navigation platform that enables physicians to see a patient’s internal soft tissue, vascular, organ and skeletal structures in 3D based on their CT images.
Additionally, it combines CT imaging with ultrasound, allowing 3D holographic images to be viewed anatomically under the patient’s skin, allowing providers to perform minimally invasive procedures such as tumor ablation and biopsy. A holographic beam of light is also used to track and indicate the path of a physician’s instrument for surgical navigation.
THE BIGGER TREND
In March, MediView XR scored $15 million in strategic fundinga year after securing one Investment of 9.9 million US dollars.
Founded in December, the Cleveland-based company announced It entered into an expertise agreement with the Mayo Clinic in which the healthcare system would provide technology, clinical expertise and research expertise to accelerate innovation and advance procedural augmented reality solutions.
A month earlier MediView XR announced a collaboration with GE Healthcare to co-develop the OmnifyXR Interventional Suite System, which combines GE’s imaging technologies with MediView’s augmented reality and surgical navigation expertise to enable physicians to evaluate multiple holographic representations of live 3D imaging .
Other companies offering an augmented reality surgical navigation platform are Augmedics, which raised $82.5 million in Series D funding last month, and Osso VR, which raised $66 million in Series C funding in 2022 and $27 million in Series B funding in 2022 received in 2021.
